Cullinan Therapeutics to present CLN-978 Phase 1 data for RA and SLE at EULAR 2026

Cullinan Therapeutics announced initial clinical data from two Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, showing favorable safety profile and robust B cell depletion with early signals of clinical activity in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus patients. The data presentation at EULAR Congress in June 2026 demonstrates progress in the company's pipeline for autoimmune diseases, potentially validating the therapeutic approach and advancing toward later-stage development.